Cubresa Inc. has received its first US Food and Drug Administration 510(k) clearance for BrainPET, a dedicated positron-emission tomography system designed to operate within compatible magnetic resonance infrastructure and provide simultaneous PET-MR brain imaging without requiring a hospital to purchase another complete whole-body hybrid scanner. FDA records identify K253963 as a traditional 510(k) for a Class II tomographic imaging system combining emission computed tomography with magnetic resonance, with the agency receiving Cubresa’s application on December 11, 2025 and issuing its substantial-equivalence decision on July 17, 2026 before the company publicly announced the milestone in August.
Cubresa’s commercial strategy centers on a removable PET insert rather than a fixed whole-body PET-MR installation. The initial cleared configuration is designed to integrate with Siemens Biograph mMR infrastructure, allowing institutions that already possess expensive MRI/PET architecture to add a dedicated brain PET capability focused on neurological imaging. The company argues that this retrofit model can lower capital and space requirements while improving PET sensitivity and spatial resolution for the brain, although those performance claims must be interpreted according to the cleared device specifications rather than as evidence that BrainPET is diagnostically superior across every neurological disease.
Why combine PET and MRI for brain imaging?
PET and MRI provide fundamentally different information. MRI offers detailed structural imaging and specialized sequences capable of characterizing anatomy, tissue properties and vascular or functional changes, while PET uses radiotracers to measure molecular and biochemical processes such as glucose metabolism or the presence of specific disease-associated proteins.
Combining the modalities can allow physicians to align molecular abnormalities with high-resolution brain anatomy in the same examination. This can be useful in areas including neurodegenerative disease, epilepsy and brain tumors, where the spatial relationship between molecular activity and anatomical structures may influence interpretation.
Simultaneous acquisition can also reduce registration problems that occur when PET and MRI are performed separately at different times and patient positions. The patient remains in the same imaging geometry while both datasets are collected, potentially producing more precise multimodal alignment.
What makes BrainPET different from a conventional whole-body PET-MR scanner?
Whole-body hybrid systems must be capable of imaging anatomy from the head through large portions of the body, requiring large detector geometry and substantial capital investment. Cubresa’s BrainPET instead concentrates the PET detector around the head, allowing the system to optimize geometry for neurological imaging rather than accommodate whole-body examinations.
The insert is designed to fit inside an MRI bore and can be removed when conventional MRI or other system functions are required. This modular approach could be particularly attractive for institutions that already have compatible imaging infrastructure but cannot justify another dedicated room and complete scanner for neurological PET.
FDA classified BrainPET under regulation 21 CFR 892.1200 and product code OUO, covering tomographic imagers that combine emission computed tomography with nuclear magnetic resonance. The device was found substantially equivalent through the 510(k) pathway, meaning this should be described as FDA clearance rather than FDA approval of a novel Class III system.
Why is dedicated brain PET becoming more relevant in Alzheimer’s disease?
Alzheimer’s disease is increasingly being defined and treated according to biological pathology rather than clinical symptoms alone. PET tracers can visualize amyloid or tau pathology, while disease-modifying therapies may require confirmation that the relevant target is present before treatment.
Blood biomarkers are likely to reduce the number of patients who require PET purely for initial amyloid assessment, but PET retains important advantages when a spatial image of pathology is needed, results are ambiguous or clinicians need a more definitive assessment.
A dedicated brain scanner could therefore benefit from growth in biomarker-driven neurology even if whole-body PET-MR remains a relatively specialized technology. Higher sensitivity may also enable changes in acquisition time or injected tracer dose, although the exact clinical trade-offs depend on scanner performance and individual protocols and should not be assumed solely from the device’s geometry.
How does the Siemens relationship influence Cubresa’s commercial opportunity?
Cubresa previously established a Master Interface Agreement with Siemens Healthineers covering BrainPET integration with Siemens systems and expanded that relationship to include additional MRI architecture. The agreement provides technical interoperability but does not mean Siemens owns or automatically sells BrainPET in every market.
Compatibility with an established scanner base can reduce adoption barriers because hospitals are typically reluctant to purchase imaging technology that requires replacing otherwise functional capital equipment. A validated retrofit gives Cubresa a defined initial customer population and can allow facilities to upgrade neurological imaging capabilities incrementally.
The limitation is that the commercial opportunity initially depends heavily on the installed base of compatible systems. Broader adoption could eventually require support for additional MRI platforms and regulatory submissions covering those configurations.
Could BrainPET change the economics of PET-MR adoption?
PET-MR has compelling scientific capabilities but has generally remained less widely deployed than PET-CT, partly because of cost, infrastructure complexity and uncertainty about whether the additional MRI information justifies the investment across enough clinical cases.
Cubresa is attempting to alter that calculation by separating the brain application from the need to acquire another entire whole-body system. Hospitals with compatible infrastructure could add dedicated neurological PET capacity using a smaller piece of equipment, potentially shifting the financial decision from construction of a new imaging suite toward an upgrade.
That does not eliminate other costs. PET still requires access to appropriate radiotracers, nuclear-medicine personnel, radiation-safety infrastructure, physicist support and reimbursement for the relevant examinations. The insert model lowers one part of the capital barrier rather than converting PET into inexpensive routine imaging.
What will determine whether FDA clearance turns into significant clinical adoption?
Image quality and workflow will be decisive. Neurologists and nuclear-medicine physicians will need to determine whether the dedicated geometry produces clinically meaningful advantages over existing PET-CT or PET-MR systems, while technologists will care about how quickly BrainPET can be installed, removed, calibrated and integrated into routine scanner schedules.
Clinical evidence will also need to expand. A 510(k) clearance establishes substantial equivalence for the authorized imaging function, not superiority in diagnosing Alzheimer’s disease, epilepsy or brain cancer. Disease-specific adoption will depend on studies showing how the resulting PET-MR information influences interpretation and patient management.
Cubresa has nevertheless crossed the regulatory threshold that separates an investigational imaging platform from one that can enter US clinical use. The company submitted its first 510(k) only in late 2025 and now has a cleared Class II brain PET-MR product built around an unusual retrofit model.
The broader significance lies in that architecture. Advanced imaging has historically required hospitals to buy progressively larger and more expensive complete scanners. BrainPET proposes another route: place a specialized detector inside infrastructure the hospital already owns and concentrate the performance on one organ where molecular imaging is becoming increasingly important.
Whether that model can expand beyond specialized academic centers will depend on economics and evidence, but FDA clearance gives Cubresa the opportunity to find out in actual clinical practice rather than research laboratories alone.
